August 27, 2019
Both florbetapir-PET and fluorodeoxyglucose (FDG) PET scans are approved diagnostic methods for Alzheimer's disease, but a new study by researchers at Thomas Jefferson University and Penn Medicine have identified FDG PET as more effective for measuring cognitive function. Marcus Institute director of research Andrew Newberg, MD, states, "Amyloid imaging has a value in diagnosing or ruling out Alzheimer's disease, but it's a bit like all or nothing. Our study shows that it can reveal disease, but you wouldn't be able to differentiate between someone who had very mild or very severe symptoms."
The results of the study were detailed in the Journal of Alzheimer's Disease.